

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS
OF THE THIRD SESSION OF THE BOARD;
AND
CLOSURE OF H SHARE REGISTER OF MEMBERS
FOR THE 2026 THIRD
EXTRAORDINARY GENERAL MEETING**

**PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS OF
THE THIRD SESSION OF THE BOARD**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) announces that the term of office of the second session of the Board will expire in November 2026. At the Board meeting held on October 26, 2026, the Board resolved to conduct the re-election of the third session of the Board (the “**Third Session of the Board**”), subject to the approval of the shareholders of the Company (the “**Shareholders**”) at the 2026 third extraordinary general meeting of the Company (the “**EGM**”) to be convened by the Board on November 13, 2026.

The Third Session of the Board will consist of nine Directors, including three executive Directors, three non-executive Directors and three independent non-executive Directors. The term of office for each proposed Director shall be three years commencing from the date of approval at the EGM.

The Board has proposed the re-election of all the existing Directors of the current session of the Board as Directors of the Third Session of the Board, subject to the approval of the Shareholders at the EGM. The proposed re-election are as follows:

- (i) the re-election of the current executive Director, Mr. WANG Guohui (王國輝), as an executive Director of the Third Session of the Board;
- (ii) the re-election of the current executive Director, Ms. ZHANG Kun (張坤), as an executive Director of the Third Session of the Board;
- (iii) the re-election of the current executive Director, Mr. WEI Jiawei (韋家威), as an executive Director of the Third Session of the Board;
- (iv) the re-election of the current non-executive Director, Mr. CHEN Gang (陳剛), as a non-executive Director of the Third Session of the Board;
- (v) the re-election of the current non-executive Director, Mr. CHEN Shaoxiong (陳少雄), as a non-executive Director of the Third Session of the Board;
- (vi) the re-election of the current independent non-executive Director, Mr. GUO Shaomu (郭少牧), as an independent non-executive Director of the Third Session of the Board;
- (vii) the re-election of the current independent non-executive Director, Mr. FENG Xiangqian (馮向前), as an independent non-executive Director of the Third Session of the Board; and
- (viii) the re-election of the current independent non-executive Director, Mr. GONG Ping (龔平), as an independent non-executive Director of the Third Session of the Board.

In addition, the Board has proposed the appointment of the following person as a non-executive Director of the Third Session of the Board, subject to the approval of the Shareholders at the EGM:

- (i) the appointment of Mr. LU Xubo (魯旭波) as a non-executive Director of the Third Session of the Board.

Biographical details of Mr. LU Xubo (魯旭波) required to be disclosed in accordance with Rule 13.51(2) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Listing Rules**”) are set out in the Appendix to this announcement.

All proposed Directors have respectively confirmed that they have no disagreement in respect of the nomination. Each of the proposed independent non-executive Directors has satisfied the requirement of independence as set out in Rule 3.13 of the Listing Rules.

Ordinary resolutions will be proposed at the EGM for the re-election and appointment of the proposed Directors of the Third Session of the Board.

CLOSURE OF H SHARE REGISTER OF MEMBERS

For determining the list of shareholders of H shares (“**H Shares**”) of the Company who are entitled to attend and vote at the EGM, the H Shares register of members will be closed from Tuesday, November 10, 2026 to Friday, November 13, 2026, both days inclusive. The shareholders of H Shares whose names appear on the H Shares register of members of the Company on Friday, November 13, 2026 will be entitled to attend and vote at the EGM. During the book closure period, no share transfers will be registered. In order to be eligible for attending and voting at the EGM, all transfers documents of H Shares accompanied by the relevant share certificates must be lodged with the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, November 9, 2026 for registration.

A circular containing, among other things, further details in relation to the proposed re-election and appointment of Directors, including the biographical details of the proposed Directors required to be disclosed under Rule 13.51(2) of the Listing Rules, together with a notice of the EGM will be despatched to the Shareholders in due course.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, October 26, 2026

As at the date of this announcement, the Board comprises Mr. WANG Guohui, Ms. ZHANG Kun and Mr. WEI Jiawei as executive Directors; Mr. CHEN Shaoxiong and Mr. CHEN Gang as non-executive Directors; and Mr. GUO Shaomu, Mr. FENG Xiangqian and Mr. GONG Ping as independent non-executive Directors.

APPENDIX

BIOGRAPHICAL DETAILS OF MR. LU Xubo (魯旭波), the proposed non-executive Director

Mr. LU Xubo (魯旭波), aged 46, has served as a founding partner and the head of risk and compliance of FV Asset Management Hangzhou Co., Ltd. (杭州安益資產管理有限公司) since July 2016.

Mr. Lu has served as a director of Zhejiang Xiangyin Technology Co., Ltd. (浙江祥音科技有限公司) since April 2017, and as the secretary-general (秘書長) of Zhejiang Comfort Think Tank Education Foundation (浙江安逸智庫教育基金會) since January 2018. He has served as an independent non-executive director of Shanghai Bio-heart Biological Technology Co., Ltd. (上海百心安生物技術股份有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 2185.HK), since November 2020.

From October 2004 to October 2005, Mr. Lu was responsible for legal supervision at Fuyang Fuchun Shanju Leisure Business Co., Ltd. (富陽富春山居休閒事業有限公司). From December 2005 to June 2016, Mr. Lu served as assistant to the board secretary, securities affairs representative, investment department manager, supervisor, director and board secretary at Zhejiang Kangsheng Co., Ltd. (浙江康盛股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002418.SZ). From June 2020 to September 2020, Mr. Lu served as an executive director and the general manager of Hangzhou Zhidian Network Technology Co., Ltd. (杭州質點網絡科技有限公司). From August 2014 to August 2020 and from June 2022 to March 2025, Mr. Lu served as an independent director of Shanghai Kinetic Medical Co., Ltd. (上海凱利泰醫療科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300326.SZ).

Mr. Lu obtained his bachelor's degree in law from Zhejiang University of Finance and Economics (浙江財經大學) in the PRC in June 2003. He obtained the Legal Professional Qualification of the PRC (中華人民共和國法律職業資格), issued by the Ministry of Justice of the PRC, in February 2008.

Save as disclosed above, as at the date of this announcement, Mr. Lu does not and has not held any directorships in any other listed public companies in the last three years prior to the date of this announcement, of which the securities are listed on any securities market in Hong Kong or overseas, and nor does Mr. Lu have other major appointments and professional qualifications. Furthermore, Mr. Lu has no relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company, nor does Mr. Lu have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Also, Mr. Lu does not hold any other positions in the Company or other members of the Group.